PharmiWeb.com - Global Pharma News & Resources
08-Jul-2019

Cancer Supportive Care Drugs Market Size to Cross USD 21.8 Bn by 2026

The Global Cancer Supportive Care Drugs Market Size is expected to reach USD 21.8 Billion by 2026 and growing CAGR around 1.6 % during the forecast period from 2019 to 2026.

Cancer Supportive Care Drugs Market (By Therapeutic Class: NSAIDs, Granulocyte-colony Stimulating Factors, Bisphosphonates, Erythropoiesis Stimulating Agents, Anti-emetics, Opioids) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026, Published by Acumen Research and Consulting.

The key drivers of the cancer therapy market are growing incidence of cancer, quickly expanding the bio-medicine sector, increased study activities in the field of academia and clinical research, increased cooperation among awareness-raising organisations, changing lifestyles, advances in the field of health services, new therapies and an increase in per capita income. Increased development has led to a significant improvement in cancer research and therapy in the biopharmaceutical sector. Drug discovery developments have led to lower mortality rates among patients with cancer. The management of cancer pain has improved significantly however, because of the bad physician evaluation and absence of appropriate understanding of recent medicines and therapy, these improvements were underused. The significant constraints of the cancer-supporting therapeutic industry are the lack of knowledge about various therapeutic systems used in emerging economies for supporting cancer, elevated therapy price, strict government regulation and unfavorable rates of repayment.

Supporting cancer care focuses on prevention and treatment of cancer-related diseases and side effects. The key cancer side effects include anemia, neutropenia, nausea, vomiting, bone metastasis and pain. The increase in the amount of individuals affected by anti-cancer therapies will drive the global market. The greater efficacy of medicinal supportives (e.g., G-CSFs), opioid analgesics, erythropoietins and antiemetic products), among others, is expected to boost the world market for cancer supportive medicinal products. These pharmaceuticals should be highly effective in managing and treating the adverse effects of cancer in the near future.

Free Download Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1486

The therapeutic classes of G-CSF and ESAs are experiencing a basic change from biological to biological. During the prediction, fresh product lancements and elevated unmet needs will increase considerably in the market for cancer pain, chemotherapy-induced nausea and vomiting, and cancer-induced bone illnesses. A change from opioid to nonopioid therapies has been estimated in the cancer pain markets. The change will be supported by patent loss, elevated mortality, addiction and significant narcotic safety problems.

Cancer is defined by an unusual uncontrolled cell proliferation, triggered by mutations that lead to migration of the tumor to various areas of the human body. This is called metastasis in the migration of tumor cells. Therapeutics to support cancer include medicines for the prevention and treatment of cancer. These decrease the side effects induced by cancer treatments, which help to increase people's life expectancy.

Key Findings

In 2018, the worldwide CIA ESAs market was evaluated by therapeutic class at USD 1.838 million and is expected to decrease by 6.2 percent during the projected era. Because of the expiration of significant products such as Epogen, the biological market segment is expected to lose its market share.

North America has been market leader in cancer-focused medicines in 2018 and is anticipated to continue in the forecast era.

Due to better health facilities and growing public projects, Asia Pacific is anticipated to be showing profitable development during the period forecast.

Non-opioids like Tanezumab and HTX-011 are included in late phase pipeline goods. More efficient with a superior security profile have demonstrated new immunotherapies against PD-1 ligands and PD-L1 proteins

Key Players amp; Strategies

Merck, Roche, Amgen, Johnson amp; Johnson, Heron Pharma, Helsinn Healthcare, and Tesaro are some of the players working on this market. During the forecast era, the approval of Sustol and Cinvanti should provide Heron Pharma with a important market chance. The company also has a Phase III cancer pain candidate.

Several companies, most notably Roche and Amgen, affected patent expirations and rising biosimilar competition. Some of the main players include Teva Pharmaceuticals, Hospira, Sandoz, 3SBio and BioSidus.

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Crime Risk Report
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Crime Risk Report Market By Therapeutic Class
1.2.2.1. Global Crime Risk Report Market Revenue and Growth Rate Comparison By Therapeutic Class (2015-2026)
1.2.2.2. Global Crime Risk Report Market Revenue Share By Therapeutic Class in 2017
1.2.2.3. NSAIDs
1.2.2.4. Granulocyte-colony Stimulating Factors
1.2.2.5. Bisphosphonates
1.2.2.6. Erythropoiesis Stimulating Agents
1.2.2.7. Anti-emetics
1.2.2.8. Opioids
1.2.3. Crime Risk Report Market by Geography
1.2.3.1. Global Crime Risk Report Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.3.2. North America Crime Risk Report Market Revenue and Growth Rate (2015-2026)
1.2.3.3. Europe Crime Risk Report Market Revenue and Growth Rate (2015-2026)
1.2.3.4. Asia-Pacific Crime Risk Report Market Revenue and Growth Rate (2015-2026)
1.2.3.5. Latin America Crime Risk Report Market Revenue and Growth Rate (2015-2026)
1.2.3.6. Middle East and Africa (MEA) Crime Risk Report Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porterrsquo;s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Crime Risk Report Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Crime Risk Report Major Manufacturers in 2017
3.3. Ramp;D Status and Technology Source of Global Crime Risk Report Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Crime Risk Report Major Manufacturers in 2017

CHAPTER 4. CANCER SUPPORTIVE CARE DRUGS MARKET BY THERAPEUTIC CLASS

4.1. Global Crime Risk Report Revenue By Therapeutic Class
4.2. NSAIDs
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Granulocyte-colony Stimulating Factors
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Bisphosphonates
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Erythropoiesis Stimulating Agents
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Anti-emetics
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.7. Opioids
4.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET BY COUNTRY

5.1. North America Crime Risk Report Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2. North America Crime Risk Report Market Revenue Share Comparison, 2015 amp; 2026 (%)
5.3. U.S.
5.3.1. U.S. Crime Risk Report Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)
5.4. Canada
5.4.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)
5.5. Mexico
5.5.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)

CHAPTER 6. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET BY COUNTRY

6.1. Europe Crime Risk Report Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2. Europe Crime Risk Report Market Revenue Share Comparison, 2015 amp; 2026 (%)
6.3. UK
6.3.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)
6.4. Germany
6.4.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)
6.5. France
6.5.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)
6.6. Spain
6.6.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)
6.7. Rest of Europe
6.7.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)

CHAPTER 7. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET BY COUNTRY

7.1. Asia-Pacific Crime Risk Report Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. Asia-Pacific Crime Risk Report Market Revenue Share Comparison, 2015 amp; 2026 (%)
7.3. China
7.3.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)
7.4. Japan
7.4.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)
7.5. India
7.5.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)
7.6. Australia
7.6.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)
7.7. South Korea
7.7.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)
7.8. Rest of Asia-Pacific
7.8.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)

CHAPTER 8. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET BY COUNTRY

8.1. Latin America Crime Risk Report Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Latin America Crime Risk Report Market Revenue Share Comparison, 2015 amp; 2026 (%)
8.3. Brazil
8.3.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)
8.4. Argentina
8.4.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)
8.5. Rest of Latin America
8.5.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)

CHAPTER 9. MIDDLE EAST CANCER SUPPORTIVE CARE DRUGS MARKET BY COUNTRY

9.1. Middle East Crime Risk Report Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Middle East Crime Risk Report Market Revenue Share Comparison, 2015 amp; 2026 (%)
9.3. Saudi Arabia
9.3.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)
9.4. UAE
9.4.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)
9.5. Rest of Middle East
9.5.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)

CHAPTER 10. AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET BY COUNTRY

10.1. Africa Crime Risk Report Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Africa Crime Risk Report Market Revenue Share Comparison, 2015 amp; 2026 (%)
10.3. South Africa
10.3.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)
10.4. Egypt
10.4.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)
10.5. Rest of Africa
10.5.1. Market Revenue and Forecast By Therapeutic Class, 2015 - 2026 ($Million)

CHAPTER 11. COMPANY PROFILE

11.1. Merck
11.1.1. Company Snapshot
11.1.2. Overview
11.1.3. Financial Overview
11.1.4. Product Portfolio
11.1.5. Key Developments
11.1.6. Strategies
11.2. Roche
11.2.1. Company Snapshot
11.2.2. Overview
11.2.3. Financial Overview
11.2.4. Product Portfolio
11.2.5. Key Developments
11.2.6. Strategies
11.3. Amgen
11.3.1. Company Snapshot
11.3.2. Overview
11.3.3. Financial Overview
11.3.4. Product Portfolio
11.3.5. Key Developments
11.3.6. Strategies
11.4. Johnson amp; Johnson
11.4.1. Company Snapshot
11.4.2. Overview
11.4.3. Financial Overview
11.4.4. Product Portfolio
11.4.5. Key Developments
11.4.6. Strategies
11.5. Heron Pharma
11.5.1. Company Snapshot
11.5.2. Overview
11.5.3. Financial Overview
11.5.4. Product Portfolio
11.5.5. Key Developments
11.5.6. Strategies
11.6. Helsinn Healthcare
11.6.1. Company Snapshot
11.6.2. Overview
11.6.3. Financial Overview
11.6.4. Product Portfolio
11.6.5. Key Developments
11.6.6. Strategies
11.7. Tesaro
11.7.1. Company Snapshot
11.7.2. Overview
11.7.3. Financial Overview
11.7.4. Product Portfolio
11.7.5. Key Developments
11.7.6. Strategies
11.8. Others
11.8.1. Company Snapshot
11.8.2. Overview
11.8.3. Financial Overview
11.8.4. Product Portfolio
11.8.5. Key Developments
11.8.6. Strategies

CHAPTER 12. RESEARCH APPROACH

12.1. Research Methodology
12.1.1. Initial Data Search
12.1.2. Secondary Research
12.1.3. Primary Research
12.2. Assumptions and Scope

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this Premium Research Report - https://www.acumenresearchandconsulting.com/buy-now/0/1486

Would like to place an order or any question, please feel free to contact atsales@acumenresearchandconsulting.com| +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to makefact baseddecisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Editor Details

Last Updated: 08-Jul-2019